Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

80%

4 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 4
3(75.0%)
Phase 3
1(25.0%)
4Total
Phase 4(3)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07384429Phase 4Recruiting

Effects of Lemborexant on Motor-sleep Comorbidity in Parkinson's Disease

Role: collaborator

NCT02787746Phase 4Completed

Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

Role: collaborator

NCT01284647Phase 4Completed

A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis

Role: collaborator

NCT01299077Completed

Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China

Role: lead

NCT01355276Phase 3Completed

Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Role: lead

All 5 trials loaded